Instead, we suggest the existence of complex feedback mechanism where secondarily activated caspase-8 can further cleave the effector caspases, additionally amplifying the caspase cascade in the prostate cancer cells treated with cisplatin/LA-12 and TRAIL combination. The gene discussed is CASP8; the disease is prostate carcinoma.